The expression level of the tumor suppressor retinoblastoma protein (Rb) influences the antileukemic efficacy of erucylphospho-N,N,N- trimethylpropylammonium (ErPC3)

Cancer Biology and Therapy

Volumn 6, Issue 6, 2007, Pages 930-935

  Yosifov, Deyan Y ^a,b   Dineva, Ilina K ^a,b   Zaharieva, Maya M ^a,b   Konstantinov, Spiro M ^a,b   Berger, Martin R ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

Alkylphosphocholines,erucylphospho N,N,N trimethylpropylammonium (erufosine); Antisense; Chronic myeloid leukemia (CML); Cytotoxic efficacy; Rb

Indexed keywords

ERUCYLPHOSPHO N,N,N TRIMETHYLPROPYLAMMONIUM; PHOSPHORYLCHOLINE; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ERUCYLPHOSPHO-N,N,N-TRIMETHYLPROPYLAMMONIUM; OLIGONUCLEOTIDE; ORGANOPHOSPHATE; QUATERNARY AMMONIUM DERIVATIVE;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN K 562; CLONOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA; NUCLEIC ACID PROBE; PROTEIN BLOOD LEVEL; BIOSYNTHESIS; CELL SURVIVAL; CHEMISTRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHOSPHORYLATION; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, RETINOBLASTOMA; HUMANS; INHIBITORY CONCENTRATION 50; K562 CELLS; OLIGONUCLEOTIDES; PHOSPHORIC ACID ESTERS; PHOSPHORYLATION; QUATERNARY AMMONIUM COMPOUNDS; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEINS;

EID: 42449105737     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.6.4188     Document Type: Article

References (25)

1. Eibl H, Engel J. Synthesis of hexadecylphosphocholine (Miltefosine): New drugs in cancer therapy. Prog Exp Tumor Res 1992; 34:1-5.
2. Konstantinov SM, Topashka-Ancheva M, Benner A, Berger MR. Alkylphosphocholines: Effects on human leukemic cell lines and normal bone marrow cells. Int J Cancer 1998; 77:778-86.
3. Konstantinov SM, Eibl H, Berger MR. BCR-ABL influences the antileukaemic efficacy of alkylphosphocholines. Br J Haematol 1999; 107:365-74.
4. Konstantinov SM, Georgieva MC, Topashka-Ancheva M, Eibl H, Berger MR. Combination with an antisense oligonucleotide synergistically improves the antileukemic efficacy of erucylphospho-N,N,N-trimethylpropylammonium in chronic myeloid leukemia cell lines. Mol Cancer Ther 2002; 1:877-74.
5. Stekar J, Hilgard P, Klenner T. Opposite effect of miltefosine on the antineoplastic activity and haematological toxicity of cyclophosphamide. Eur J Cancer 1995; 31A:372-4.
6. Lucas L, Hernandez-Alcoceba R, Penalva V, Lacal JC. Modulation of phospholipase D by hexadecylphosphorylcholine: A putative novel mechanism for its antitumoral activity. Oncogene 2001; 20:1110-7.
7. Arndt D, Zeisig R, Eue I, Sternberg B, Fichtner I. Antineoplastic activity of sterically stabilized alkylphosphocholine liposomes in human breast carcinomas. Breast Cancer Res Treat 1997; 43:237-46.
8. 2+-ATPase activity of rat brain synaptosomes and leukocyte membranes. Int Immunopharmacol 2001; 1:1321-9.
9. Berger MR, Tsoneva I, Konstantinov SM, Eibl H. Induction of apoptosis by erucylphospho-N,N,N-trimethylpropylammonium is associated with changes in signal molecule expression and location. Ann N Y Acad Sci 2003; 1010:307-10.
10. Matzke A, Massing U, Krug HF. Killing tumour cells by alkylphospho-cholines: Evidence for involvement of CD95. Eur J Cell Biol 2001; 80:1-10.
11. Oberle C, Massing U, Krug HF. On the mechanism of alkylphosphocholine (APC)- induced apoptosis in tumour cells. Biol Chem 2005; 386:237-45.
12. Ward PD, Ouyang H, Thakker DR. Role of phospholipase C-β in the modulation of epithelial tight junction permeability. J Pharmacol Exp Ther 2003; 304:689-698.
13. DeGregori J. The Rb network. J Cell Sci 2004; 117:3411-3.
14. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002; 2:103-12.
15. Liu H, Dibling B, Spike B, Dirlam A, Macleod K. New roles for the RB tumor suppressor protein. Curr Opin Genet Dev 2002; 14:55-64.
16. V12-induced cellular senescence. EMBO J 2005; 24:3301-12.
17. Wang JYJ. Nucleo-cytoplasmic communication in apoptotic response to genotoxic and inflammatory stress. Cell Res 2005; 15:43-8.
18. Nagano K, Itagaki C, Izumi T, Nunomura K, Soda Y, Tani K, Takahashi N, Takenawa T, Isobe T. Rb plays a role in survival of Abl-dependent human tumor cells as a downstream effector of Abl tyrosine kinase. Oncogene 2006; 25:493-502.
19. Chau BN, Wang JYJ. Coordinated regulation of life and death by RB. Nat Rev Cancer 2003; 3:130-8.
20. Berger MR, Sobottka S, Konstantinov SM, Eibl H. Erucylphosphocholine is the prototype of i.v. injectable alkylphosphocholines. Drugs Today 1998; 34:73-81.
21. Konstantinov SM, Eibl H, Berger MR. Alkylphosphocholines induce apoptosis in HL-60 and U-937 leukemic cells. Cancer Chemother Pharmacol 1998; 41:210-6.
22. Mossmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 139:55-63.
23. Ohba H, Zhelev Z, Bakalova R, Ewis A, Omori T, Ishikawa M, Shinohara Y, Baba Y. Inhibition of bcr-abl and/or c-abl gene expression by small interfering, double-stranded RNAs: Cross-talk with cell proliferation factors and other oncogenes. Cancer 2004; 101:1390-403.
24. Lozano G, Zambetti GP. Gankyrin: An intriguing name for a novel regulator of p53 and RB. Cancer Cell 2005; 8:3-4.
25. Yun S, Sawyer GJ, Zhang X, Gustafsson K, Fabre JW. Specific suppression of interleukin 2 biosynthesis by synthetic antisense oligodeoxynucleotides does not influence allograft rejection. Transplantation 2000; 69:2586-92.